192 related articles for article (PubMed ID: 14520690)
1. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients.
Tutton MG; George ML; Eccles SA; Burton S; Swift RI; Abulafi AM
Int J Cancer; 2003 Nov; 107(4):541-50. PubMed ID: 14520690
[TBL] [Abstract][Full Text] [Related]
2. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer.
Langenskiöld M; Holmdahl L; Falk P; Ivarsson ML
Int J Colorectal Dis; 2005 May; 20(3):245-52. PubMed ID: 15592677
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
4. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
5. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer.
Horiuchi S; Yamamoto H; Min Y; Adachi Y; Itoh F; Imai K
J Pathol; 2003 Aug; 200(5):568-76. PubMed ID: 12898592
[TBL] [Abstract][Full Text] [Related]
6. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
[TBL] [Abstract][Full Text] [Related]
7. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
8. Measuring gelatinase activity in colorectal cancer.
Baker EA; Leaper DJ
Eur J Surg Oncol; 2002 Feb; 28(1):24-9. PubMed ID: 11869009
[TBL] [Abstract][Full Text] [Related]
9. Plasma gelatinase activity does not reflect disease activity after operation for colorectal cancer.
Waas ET; Wobbes T; Lomme RM; Hendriks T
Oncology; 2005; 68(2-3):256-62. PubMed ID: 16015042
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer.
Chu D; Zhao Z; Zhou Y; Li Y; Li J; Zheng J; Zhao Q; Wang W
Ann Surg Oncol; 2012 Jan; 19(1):318-25. PubMed ID: 21455597
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of plasma MMP-2 and MMP-9 levels as biomarkers for tumor expression in breast cancer patients in Egypt.
Alrehaili AA; Gharib AF; Karam RA; Alhakami RA; El Sawy WH; Abd Elrahman TM
Mol Biol Rep; 2020 Feb; 47(2):1153-1160. PubMed ID: 31820313
[TBL] [Abstract][Full Text] [Related]
12. [Expression of MMP-2, MMP-9 and collagen type IV and their relationship in colorectal carcinomas].
Wu W; He JT; Ruan JD; Wang RB; Zhang YD
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Sep; 24(9):908-9. PubMed ID: 18782525
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinase-1 in human colorectal carcinoma.
Shiozawa J; Ito M; Nakayama T; Nakashima M; Kohno S; Sekine I
Mod Pathol; 2000 Sep; 13(9):925-33. PubMed ID: 11007031
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase.
Collins HM; Morris TM; Watson SA
Br J Cancer; 2001 Jun; 84(12):1664-70. PubMed ID: 11401321
[TBL] [Abstract][Full Text] [Related]
15. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
16. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer.
Oshima T; Kunisaki C; Yoshihara K; Yamada R; Yamamoto N; Sato T; Makino H; Yamagishi S; Nagano Y; Fujii S; Shiozawa M; Akaike M; Wada N; Rino Y; Masuda M; Tanaka K; Imada T
Oncol Rep; 2008 May; 19(5):1285-91. PubMed ID: 18425389
[TBL] [Abstract][Full Text] [Related]
19. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
20. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer.
Lubbe WJ; Zhou ZY; Fu W; Zuzga D; Schulz S; Fridman R; Muschel RJ; Waldman SA; Pitari GM
Clin Cancer Res; 2006 Mar; 12(6):1876-82. PubMed ID: 16551873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
